{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:37:14Z","timestamp":1792103834320,"version":"4.4.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Sichuan Province Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["academicradiology.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.acra.2025.01.003","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T15:24:22Z","timestamp":1737473062000},"page":"6514-6527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of Metabolic Dysfunction-Associated Fatty\/Steatotic Liver Disease on Hepatocellular Carcinoma Incidence and Long-Term Prognosis Post-Liver Resection: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"32","author":[{"given":"Qingyan","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diao","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acra.2025.01.003_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","article-title":"Management of hepatocellular carcinoma: a review","volume":"158","author":"Brown","year":"2023","journal-title":"JAMA Surg"},{"key":"10.1016\/j.acra.2025.01.003_bib2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.acra.2025.01.003_bib3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: new trends","volume":"72","author":"Singal","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.acra.2025.01.003_bib4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.acra.2025.01.003_bib5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"23","author":"Tan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acra.2025.01.003_bib6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"Younossi","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.acra.2025.01.003_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.acra.2025.01.003_bib8","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.acra.2025.01.003_bib9","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14548","article-title":"Comparison of MAFLD and NAFLD diagnostic criteria in real world","volume":"40","author":"Lin","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.acra.2025.01.003_bib10","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.acra.2025.01.003_bib11","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.acra.2025.01.003_bib12","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection: a review","volume":"319","author":"Tang","year":"2018","journal-title":"Jama"},{"key":"10.1016\/j.acra.2025.01.003_bib13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3350\/cmh.2022.0422","article-title":"Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: challenges and perspectives","volume":"29","author":"Huang","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.acra.2025.01.003_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejim.2022.11.012","article-title":"Time-trends in disease characteristics and comorbidities in patients with chronic hepatitis B in the period 1980-2020","volume":"107","author":"van der Spek","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.acra.2025.01.003_bib15","first-page":"128","article-title":"Metabolic dysfunction-associated fatty liver disease (MAFLD) and viral hepatitis","volume":"10","author":"Wang","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.acra.2025.01.003_bib16","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","article-title":"Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B","volume":"73","author":"Mak","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.acra.2025.01.003_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/JHC.S355540","article-title":"Impact of PNPLA3 p.I148M and hepatic steatosis on long-term outcomes for hepatocellular carcinoma and HBsAg seroclearance in chronic hepatitis B","volume":"9","author":"Hsueh","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.acra.2025.01.003_bib18","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.jfma.2021.10.014","article-title":"Hepatic steatosis and development of type 2 diabetes: impact of chronic hepatitis B and viral specific factors","volume":"121","author":"Yu","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.acra.2025.01.003_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejca.2018.07.008","article-title":"Association of fasting serum glucose level and type 2 diabetes with hepatocellular carcinoma in men with chronic hepatitis B infection: a large cohort study","volume":"102","author":"Kim","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.acra.2025.01.003_bib20","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3748\/wjg.v27.i4.336","article-title":"Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection","volume":"27","author":"Wang","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.acra.2025.01.003_bib21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oncolo\/oyac251","article-title":"Resection of NAFLD\/NASH-related hepatocellular carcinoma (HCC): clinical features and outcomes compared with HCC due to other etiologies","volume":"28","author":"Pal Chaudhary","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.acra.2025.01.003_bib22","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.acra.2025.01.003_bib23","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.acra.2025.01.003_bib24","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.acra.2025.01.003_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.acra.2025.01.003_bib26","first-page":"Ed000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.acra.2025.01.003_bib27","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s12072-023-10545-6","article-title":"Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic Hepatitis B","volume":"17","author":"Huang","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.acra.2025.01.003_bib28","article-title":"Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic Hepatitis B","volume":"3","author":"van Kleef","year":"2021","journal-title":"JHEP Rep: Innovation in Hepatology"},{"key":"10.1016\/j.acra.2025.01.003_bib29","article-title":"Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma","volume":"5","author":"Song","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.acra.2025.01.003_bib30","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/hepr.13830","article-title":"Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic Hepatitis B virus infection: a nationwide study","volume":"52","author":"Yun","year":"2022","journal-title":"Hepatol Res: the official journal of the Japan Society of Hepatology"},{"key":"10.1016\/j.acra.2025.01.003_bib31","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/ijc.34637","article-title":"Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients","volume":"153","author":"Kim","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.acra.2025.01.003_bib32","first-page":"14","article-title":"Metabolic-associated fatty liver disease, Hepatitis B surface antigen seroclearance, and long-term risk of hepatocellular carcinoma in chronic hepatitis B","author":"Yu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.acra.2025.01.003_bib33","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/MEG.0000000000002583","article-title":"The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with Hepatitis B cirrhosis: a propensity score matching study","volume":"35","author":"Wang","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.acra.2025.01.003_bib34","first-page":"76","article-title":"Prognostic relevance of metabolic dysfunction-associated steatohepatitis for patients with chronic Hepatitis B","volume":"11","author":"Rugivarodom","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.acra.2025.01.003_bib35","doi-asserted-by":"crossref","first-page":"1347459","DOI":"10.3389\/fphys.2024.1347459","article-title":"Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic Hepatitis B patients: a retrospective cohort study","volume":"15","author":"Lin","year":"2024","journal-title":"Front Physiol"},{"key":"10.1016\/j.acra.2025.01.003_bib36","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.cgh.2024.01.045","article-title":"Chronic viral Hepatitis B and C outweigh MASLD in the associated risk of cirrhosis and HCC","volume":"22","author":"Lee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.acra.2025.01.003_bib37","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s12072-021-10281-9","article-title":"The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study","volume":"16","author":"Chen","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.acra.2025.01.003_bib38","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jhep.2023.08.018","article-title":"Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: nationwide multigenerational cohort study","volume":"79","author":"Ebrahimi","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.acra.2025.01.003_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejso.2021.07.015","article-title":"Hepatectomy for metabolic associated fatty liver disease (MAFLD) related HCC: propensity case-matched analysis with viral- and alcohol-related HCC","volume":"48","author":"Conci","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.acra.2025.01.003_bib40","first-page":"14","article-title":"Prognostic impact of MAFLD following surgical resection of Hepatitis B virus-related hepatocellular carcinoma: a nationwide cohort study","author":"Yun","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.acra.2025.01.003_bib41","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.2147\/CMAR.S368366","article-title":"Impact of metabolic dysfunction associated fatty liver disease on the prognosis of patients with Hepatitis B virus-related hepatocellular carcinoma based on propensity score matching analysis","volume":"14","author":"Xue","year":"2022","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.acra.2025.01.003_bib42","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.hbpd.2022.04.001","article-title":"The impact of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection","volume":"22","author":"Xiong","year":"2023","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.acra.2025.01.003_bib43","article-title":"Outcomes of liver resection for metabolic dysfunction-associated fatty liver disease or chronic hepatitis B-related HCC","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.acra.2025.01.003_bib44","article-title":"Metabolic risks are increasing in non-b non-c early-stage hepatocellular carcinoma: a 10-year follow-up study","volume":"12","author":"Lin","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.acra.2025.01.003_bib45","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.7150\/jca.83779","article-title":"Sex differences in the impact of metabolic dysfunction-associated fatty liver disease on the of patients with hepatocellular carcinoma after radical resection","volume":"14","author":"Huang","year":"2023","journal-title":"J Cancer"},{"key":"10.1016\/j.acra.2025.01.003_bib46","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.cgh.2024.01.045","article-title":"Chronic viral Hepatitis B and C outweigh MASLD in the associated risk of cirrhosis and HCC","volume":"22","author":"Lee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.acra.2025.01.003_bib47","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jvh.13872","article-title":"Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: a systematic review and meta-analysis","volume":"30","author":"Zhou","year":"2023","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.acra.2025.01.003_bib48","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/apt.16469","article-title":"Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy","volume":"54","author":"Fan","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.acra.2025.01.003_bib49","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1002\/hep.31612","article-title":"Association of metabolic risk factors with risks of cancer and all-cause mortality in patients with chronic hepatitis B","volume":"73","author":"Lee","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.acra.2025.01.003_bib50","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3350\/cmh.2016.0021","article-title":"Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B","volume":"22","author":"Lee","year":"2016","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.acra.2025.01.003_bib51","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/ijc.27337","article-title":"Type 2 diabetes and hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B","volume":"131","author":"Li","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.acra.2025.01.003_bib52","doi-asserted-by":"crossref","first-page":"658","DOI":"10.23736\/S0026-4806.23.08428-8","article-title":"Chronic hepatitis B infection and diabetes mellitus: a double liver trouble?","volume":"114","author":"Abu Baker","year":"2023","journal-title":"Minerva Med"},{"key":"10.1016\/j.acra.2025.01.003_bib53","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/hep.32716","article-title":"Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes","volume":"77","author":"Mak","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.acra.2025.01.003_bib54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3350\/cmh.2022.0095","article-title":"Development and prognosis of hepatocellular carcinoma in patients with diabetes","volume":"29","author":"Nakatsuka","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.acra.2025.01.003_bib55","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.tem.2006.08.006","article-title":"Obesity and cancer risk: the role of the insulin-IGF axis","volume":"17","author":"Renehan","year":"2006","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.acra.2025.01.003_bib56","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.32439","article-title":"Diabetes medications and risk of HCC","volume":"76","author":"Plaz Torres","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.acra.2025.01.003_bib57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40121-022-00725-6","article-title":"Metabolic syndrome, nonalcoholic fatty liver disease, and chronic hepatitis B: a narrative review","volume":"12","author":"Diao","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.acra.2025.01.003_bib58","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41574-021-00584-0","article-title":"Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD","volume":"18","author":"Tamaki","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.acra.2025.01.003_bib59","article-title":"Comparing three ultrasound-based techniques for diagnosing and grading hepatic steatosis in metabolic dysfunction-associated steatotic liver disease","volume":"17","author":"Wang","year":"2024","journal-title":"Acad Radiol"},{"key":"10.1016\/j.acra.2025.01.003_bib60","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.7150\/thno.40249","article-title":"Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease","volume":"10","author":"Pirmoazen","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.acra.2025.01.003_bib61","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1148\/radiol.2021204288","article-title":"Quantification of liver fat content with CT and MRI: state of the art","volume":"301","author":"Starekova","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.acra.2025.01.003_bib62","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1148\/radiol.2015141779","article-title":"Hepatic steatosis: assessment with acoustic structure quantification of US imaging","volume":"278","author":"Son","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.acra.2025.01.003_bib63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1148\/radiol.2391050361","article-title":"Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment","volume":"239","author":"Park","year":"2006","journal-title":"Radiology"},{"key":"10.1016\/j.acra.2025.01.003_bib64","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1148\/radiol.12120896","article-title":"Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis","volume":"267","author":"Tang","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.acra.2025.01.003_bib65","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/j.1478-3231.2012.02781.x","article-title":"Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography","volume":"32","author":"Myers","year":"2012","journal-title":"Liver Int"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633225000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633225000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T16:19:53Z","timestamp":1763741993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633225000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":65,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1076633225000030"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2025.01.003","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Metabolic Dysfunction-Associated Fatty\/Steatotic Liver Disease on Hepatocellular Carcinoma Incidence and Long-Term Prognosis Post-Liver Resection: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2025.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Association of Academic Radiology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}